尼古丁类药物可能有助于治疗精神分裂症
转载请注明来自丁香园
Nicotine-like drug may help schizophrenics think
An experimental drug, which stimulates the same cell receptors as the cigarette chemical nicotine, is showing promise at improving the thinking deficits that go with schizophrenia, a problem that remains largely untreated, researchers report.
Several types of schizophrenia exist, but all fall under the broad category of "psychotic disorder," meaning the patient is not in touch with reality in one or more ways. Patients are seldom, if ever, cured of this severe mental illness, but a number of medications can improve the symptoms.
In animal trials of schizophrenia, the new drug, designated PHA-543,613, had beneficial physiologic effects and improved thinking ability, senior investigator Dr. Bruce N. Roger told Reuters Health.
Although advances have been made in the treatment of schizophrenic symptoms such as delusions and withdrawal and apathy, problems with attention and thinking processes persist, the investigators report in the Journal of Medicinal Chemistry.
Research into nicotine receptor drugs, note Rogers and colleagues at Pfizer Global Research and Development, Groton, Connecticut, was originally prompted by the observation that the heavy smoking seen in more than 80 percent of schizophrenics may be a form of self-medication.
SOURCE: Journal of Medicinal Chemistry, June 29, 2006.
尼古丁类药物有助于改善精神分裂症患者的思维能力
研究人员报道，一种实验药物，与香烟中的尼古丁一样可以刺激细胞上相同的受体，有望用于改善精神分裂症相关的思维缺损这一迄今未解决的难题。
虽然存在几种形式的精神分裂症，但均属于广泛意义上的“精神紊乱”，也就是说病人以一种或多种方式处于非现实中。很少能治愈这一严重的精神疾患，但有一些药物可以改善症状。
高级研究员Bruce N.Roger博士告诉路透社健康专栏，在动物精神分裂症试验中，一种被称为PHA-543,613的新药，显示出有益的生理效应并能改善思维能力。
尽管在治疗精神分裂症的症状比如错觉、畏缩、冷漠等方面已经取得一些进展，但注意力及思维过程等方面的问题依然存在，研究人员在医学化学杂志上如此报道。
康涅狄格州Groton市辉瑞（Pfizer）全球研发部的Rogers及其同事在研究尼古丁受体药物的过程中发现，精神分裂症患者如同时吸烟严重则80％发现有自身治疗效果，这从而启发他们研究这类药物。
来源：医学化学杂志，2006年6月29日
编者按：本文由丁香园网友雪中梅翻译。
编辑：西门吹血
An experimental drug, which stimulates the same cell receptors as the cigarette chemical nicotine, is showing promise at improving the thinking deficits that go with schizophrenia, a problem that remains largely untreated, researchers report.
Several types of schizophrenia exist, but all fall under the broad category of "psychotic disorder," meaning the patient is not in touch with reality in one or more ways. Patients are seldom, if ever, cured of this severe mental illness, but a number of medications can improve the symptoms.
In animal trials of schizophrenia, the new drug, designated PHA-543,613, had beneficial physiologic effects and improved thinking ability, senior investigator Dr. Bruce N. Roger told Reuters Health.
Although advances have been made in the treatment of schizophrenic symptoms such as delusions and withdrawal and apathy, problems with attention and thinking processes persist, the investigators report in the Journal of Medicinal Chemistry.
Research into nicotine receptor drugs, note Rogers and colleagues at Pfizer Global Research and Development, Groton, Connecticut, was originally prompted by the observation that the heavy smoking seen in more than 80 percent of schizophrenics may be a form of self-medication.
SOURCE: Journal of Medicinal Chemistry, June 29, 2006.
尼古丁类药物有助于改善精神分裂症患者的思维能力
研究人员报道，一种实验药物，与香烟中的尼古丁一样可以刺激细胞上相同的受体，有望用于改善精神分裂症相关的思维缺损这一迄今未解决的难题。
虽然存在几种形式的精神分裂症，但均属于广泛意义上的“精神紊乱”，也就是说病人以一种或多种方式处于非现实中。很少能治愈这一严重的精神疾患，但有一些药物可以改善症状。
高级研究员Bruce N.Roger博士告诉路透社健康专栏，在动物精神分裂症试验中，一种被称为PHA-543,613的新药，显示出有益的生理效应并能改善思维能力。
尽管在治疗精神分裂症的症状比如错觉、畏缩、冷漠等方面已经取得一些进展，但注意力及思维过程等方面的问题依然存在，研究人员在医学化学杂志上如此报道。
康涅狄格州Groton市辉瑞（Pfizer）全球研发部的Rogers及其同事在研究尼古丁受体药物的过程中发现，精神分裂症患者如同时吸烟严重则80％发现有自身治疗效果，这从而启发他们研究这类药物。
来源：医学化学杂志，2006年6月29日
编者按：本文由丁香园网友雪中梅翻译。
编辑：西门吹血
作者: 雪中梅 译
| 以下网友留言只代表网友个人观点，不代表网站观点 | |||
Copyright 2000-2025 DXY.CN All Rights Reserved